Horizon Europe 2026-27: Cancer Mission
Funding opportunities under the Horizon Europe 2026-27 Work Programmes for the EU Mission: Cancer, targeting research and innovation in cancer prevention, cure, and patient quality of life.
Key facts
- Funding amount
- €3m to €15m per project
- Deadline
- 21 Sept 2027
- Region
- UK-wide
- Business type
- Innovative businesses & R&D-led teams
Get application intelligence on every opportunity
Create a free account to save opportunities and unlock fit assessments, application checklists and effort estimates with Pro.
Plain English summary
The Horizon Europe Cancer Mission offers substantial funding for collaborative research and innovation projects in cancer. These opportunities, with calls opening in February 2026 and 2027, are open to businesses, universities, and research institutes across various sectors, including health, digital, and biotechnology. Projects aim to improve cancer outcomes by advancing understanding, prevention, diagnosis, treatment, and quality of life for patients.
Never miss similar funding opportunities
Get a free weekly email containing newly added grants and funding opportunities relevant to UK businesses.
Who this is best for
- Innovative businesses & R&D-led teams
- Organisations based in UK-wide
- Projects aligned with innovation funding
- Teams seeking funding around €3m to €15m per project
Who should not apply
- Individuals applying in a personal capacity (unless explicitly permitted)
- Applicants who cannot meet the official eligibility criteria below
Eligibility checklist
Tick what applies to your organisation before applying.
Open to legal entities forming a consortium, including at least one independent legal entity established in an EU Member State and two other independent legal entities each established in different Member States or Associated Countries (including the UK).
Official source
Want funding opportunities like this delivered automatically?
Join Funding Radar UK's free weekly funding digest — built for UK small businesses, startups and SMEs.